Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cellectar Biosciences Q3 2026 Results: Net Loss of $7.97M, Loss Widens

Cellectar Biosciences reported a net loss of $20.6 million for the nine months ended September 30, 2026, as it continues to invest in its phospholipid drug conjugate platform. The company significantly improved its cash position to $24.6 million through the issuance of common stock and warrants, though management notes a continued dependence on outside capital to fund operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-8.0-4.4
EPS (diluted, $ a share)$-0.46$-1.41

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CLRB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cellectar Biosciences, Inc.: key numbers

Share price
$1.01Close, Nov 16
Market cap
$10.1M
Shares outstanding
10.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cellectar Biosciences, Inc.

All →
7:25 AM ET 8-K
Financial Results

Cellectar Biosciences Financial Results

Cellectar Biosciences reported financial results for the third quarter of 2026, highlighting progress toward a planned accelerated approval filing for iopofosine I 131 in Waldenström macroglobulinemia (WM). The company remains on track to file its NDA with the FDA in the first half of 2027 and expects to dose the first patients in its Phase 3 confirmatory trial in Q1 2027.

Term
Q3 2026

“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal.”

James Caruso, president and chief executive officer of Cellectar Biosciences

“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line.”

James Caruso, president and chief executive officer of Cellectar Biosciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.